Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

LUNG-GENEMED A doctoral training programme for next-generation LUNG-targeted non-viral GENEtic MEDicines

Coordinator
Politecnico Di Milano, Italy
Runs
1 December 2026 to 30 November 2030
Status
Running
EU funding
€3.9m
Total cost
—
Partners
22 organisations in 7 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101312053

What the project is doing

In the project's own words, from its summary on CORDIS.

The lungs play a crucial role in breathing and exchanging gases, and are vulnerable to numerous illnesses, including cystic fibrosis, cancer, asthma, and infections. The application of gene-based therapies is a crucial focus in the development of new treatments for these life-threatening conditions. The administration method is crucial for lung targeted genetic therapies: Inhalation stands out as a non-invasive route, providing ease of use, quick action, localized treatment, and fewer side effects compared to intravenous methods.

However, despite its advantages, inhaled RNA therapies have yet to gain clinical approval due to challenges in navigating the complex lung environment and ensuring effective gene delivery. In LUNG-GENEMED, we aim to develop advanced delivery systems that effectively penetrate lung barriers—such as mucus, surfactant proteins, and mucociliary clearance—to enhance treatment efficacy while minimizing dosage. We will build up a multidisciplinary network of 11 academic partners and 8 non-academic associated partners with expertise in soft matter, drug delivery, aerosolization, respiratory physiology and physiopathology and organ-on-chip technology.

We will recruit and train 13 Doctoral Candidates (DC) for generating highly skilled scientists with competencies at the cutting edge of gene therapy who will spread their acquired knowledge across Europe well beyond the timeframe of this project. The training program will focus on developing tailored genetic nanotherapeutics for lung delivery to target untreatable diseases by elucidating the intricate bio-nano interaction patterns within the lungs.

Organ-on-chip models of lungs will be used to test safety and efficacy of therapeutics, while reducing animal testing. Overall, we will tackle the current barriers arresting gene therapy by training the next generation scientists through individual training-through-research projects and secondments, scheduled in both academic and non-academic partners.

Topics

Who is involved

OrganisationCityCountryRole
Politecnico Di MilanoMilanoItalyCoordinator
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyParticipant
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyAssociatedpartner
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyParticipant
Croda Denmark A/SFrederikssundDenmarkAssociatedpartner
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Asociacion Centro De Investigacion Cooperativa En Biomateriales- Cic BiomaguneSan SebastianSpainParticipant
Fundacion Para La Investigacion Biomedica Del Hospital Universitario 12 De OctubreMadridSpainParticipant
Fundación LovexairEl Puerto De Santa MaríaSpainAssociatedpartner
Universidad Complutense De MadridMadridSpainParticipant
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainAssociatedpartner
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
FghiMontarnaudFranceAssociatedpartner
Universite De ToulouseToulouseFranceAssociatedpartner
Consorzio ItalbiotecMilanoItalyAssociatedpartner
Universita Degli Studi Di FirenzeFlorenceItalyParticipant
Astrazeneca ABSodertaeljeSwedenAssociatedpartner
Iconovo ABLundSwedenAssociatedpartner
SPARTA Biodiscovery LimitedLondonUnited KingdomAssociatedpartner
The University of BirminghamBirminghamUnited KingdomParticipant
United Kingdom Research and InnovationSwindonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI